frontiers | Frontiers in Pharmacology

TYPE Correction
PUBLISHED 02 January 2026
DOI 10.3389/fphar.2025.1764700

Check for updates

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Yuan Tian,
tianyuancherry@163.com
Yong Yang,
wolfyangy@163.com

†These authors have contributed equally to this work

RECEIVED 10 December 2025
REVISED 10 December 2025
ACCEPTED 11 December 2025
PUBLISHED 02 January 2026

CITATION
Liao W, Fan R, Du Y, Wang H, Yang Y and Tian Y (2026) Correction: Nafamostat mesilate attenuates renal fibrosis by suppressing the IL-17 signaling pathway.
Front. Pharmacol. 16:1764700.
doi: 10.3389/fphar.2025.1764700

Correction: Nafamostat mesilate attenuates renal fibrosis by suppressing the IL-17 signaling pathway

Weili Liao[2†], Rui Fan[1†], Yuman Du[1], Hairong Wang[1], Yong Yang[2*] and Yuan Tian[1*]

[1]Department of Nephrology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, China, [2]School of Public Health, Mudanjiang Medical University, Mudanjiang, China

KEYWORDS

renal interstitial fibrosis, Granzyme B, nafamostat mesylate, tubular injury, inflammation

A Correction on
Nafamostat mesilate attenuates renal fibrosis by suppressing the IL-17 signaling pathway

by Liao W, Fan R, Du Y, Wang H, Yang Y and Tian Y (2025). Front. Pharmacol. 16:1648623. doi: 10.3389/fphar.2025.1648623

The order of **Affiliations** was incorrect. The correct order is:

1 Department of Nephrology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, China.

2 School of Public Health, Mudanjiang Medical University, Mudanjiang, China.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.